{Reference Type}: Journal Article
{Title}: Comparative analysis of two novel complete genomes of myxoma virus vaccine strains.
{Author}: Volodina S;Titov I;Zhivoderov S;Yurkov S;Malogolovkin A;
{Journal}: Virus Genes
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 11
{Factor}: 2.198
{DOI}: 10.1007/s11262-024-02090-7
{Abstract}: Myxoma virus (MYXV) is a double-stranded DNA-containing virus of the family Poxviridae, genus Leporipoxvirus. MYXV is an important model virus for evolutionary and immunological research and a promising oncolytic. In this study, we sequenced and analyzed two complete genomes of MYXV virus vaccine strains B-82 and Rabbivac-B, which are widely used for vaccine production in Russia. Here, we first show that MYXV vaccine strains B-82 and Rabbivac-B share a common origin with the American recombinant MYXV MAV vaccine strain. In addition, our data suggest that the MYXV B-82 and Rabbivac-B strains contain a number of genes at the 5' and 3' ends that are identical to the virulent MYXV Lausanne strain. Several unique genetic signatures were identified in the M013L, M017L, M023, and M121R genes, helping to achieve high genetic resolution between vaccine strains. Overall, these findings highlight the evolutionary flexibility of certain genes in the MYXV genome and provide insights into the molecular epidemiology of the virus and subsequent vaccine development.